e8va12bza
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Amendment No. 4
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Avanir Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
33-0314804 |
|
|
|
(State of incorporation or organization)
|
|
(I.R.S. Employer Identification No.) |
|
|
|
101 Enterprise, Suite 300, Aliso Viejo, California
|
|
92656 |
|
|
|
(Address or principal executive offices)
|
|
(Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class |
|
Name of each exchange on which |
to be so registered |
|
each class is to be registered |
Common Stock, $0.0001 par value
|
|
The Nasdaq Stock Market LLC |
Securities to be registered pursuant to Section 12(g) of the Act: None
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the
Exchange Act and is effective pursuant to General instruction A.(c), check the following box.
þ
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the
Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.
o
Securities Act registration statement file number to which this form relates: 001-15803
EXPLANATORY NOTE
This
Amendment No. 4 to Form 8-A is being filed pursuant to Rule 12g-3
under the Securities Exchange Act of
1934, as amended (the Exchange Act) to amend the registrants registration
statement on Form 8-A/A to reflect the March 23, 2009 reincorporation of Avanir Pharmaceuticals
from California to Delaware (the Reincorporation). On March 23, 2009, Avanir
Pharmaceuticals, a California corporation (Avanir California) merged with and into Avanir
Pharmaceuticals, Inc., a Delaware corporation and a wholly-owned subsidiary of Avanir California
(the Company), with the Company as the surviving entity (the Merger). The
shareholders of Avanir California approved the Reincorporation and the Merger at the annual meeting
of shareholders of Avanir California held on February 19, 2009.
Immediately prior to the consummation of the Merger, the Company had nominal assets and
liabilities.
As a result of the Reincorporation, (i) each outstanding share of Avanir Californias Class A
common stock, no par value, issued and outstanding was automatically converted into one share of
the Companys common stock, $0.0001 par value per share (upon the Reincorporation, each outstanding
certificate representing shares of Avanir Californias Class A
common stock was deemed, without any action by the
shareholder, to represent the same number of shares of the Companys common stock; Avanir
California shareholders did not need to exchange their stock certificates as a result of the
Reincorporation); and (ii) all options and other rights to
acquire Avanir Californias Class A common stock
outstanding immediately before the Reincorporation were also automatically converted into options
and rights to acquire the same number of shares of the Companys common stock upon the same terms,
including price.
In accordance with Rule 12g-3 under the Exchange Act, the shares of common stock of the Company were deemed to be registered
under Section 12(b) of the Exchange Act as the successor to Avanir
California. The Company, as successor issuer to Avanir California, hereby
expressly adopts this Form 8-A/A as its own for all purposes of the Exchange
Act. The shares of common stock of the Company continued to be listed on the Nasdaq Global Market
under the symbol AVNR.
Prior to March 23, 2009, Avanir California corporate affairs were governed by the corporate law of
California. The rights of Avanir California shareholders were subject to Avanir Californias
articles of incorporation and bylaws. As a result of the Reincorporation, holders of Avanir
California Class A common stock are now holders of the Companys common stock, and their rights as
stockholders are governed by the Delaware General Corporation Law and the certificate of
incorporation and bylaws of the Company.
Item 1. Description of Registrants Securities to be Registered.
The Companys authorized capital stock consists of 200,000,000 shares of common stock, $0.0001 par
value per share, and 10,000,000 shares of preferred stock, $0.0001
par value per share. Immediately after the
effective time of the Merger, there were 78,236,546 shares of common stock
outstanding and no
shares of preferred stock outstanding. All shares of common stock outstanding are fully paid and
non-assessable.
Common Stock
Holders of the Companys common stock are entitled to one vote per share on all matters submitted
to a vote of stockholders and may not cumulate votes for the election of directors. Common
stockholders have the right to receive dividends when, as and if declared by the Board of Directors
from funds legally available therefor. Holders of common stock have no preemptive rights and have
no rights to convert their common stock into any other securities. The common stock is not subject
to further calls or assessments by the Company. There are no redemption or sinking fund provisions
applicable to the common stock. All outstanding shares of the Companys common stock are fully
paid and non-assessable.
Preferred Stock Purchase Rights
Pursuant to the Stockholder Rights Agreement, dated as of March 20, 2009, by and between the
Company and American Stock Transfer & Trust Company, LLC (the Rights Agreement), a
preferred stock purchase right is issued with each share of Common Stock now issued and outstanding
and issued in the future. A description of the Rights Agreement is set forth in Amendment No. 3 to
the Companys Registration Statement on Form 8-A, filed with the Securities and Exchange Commission
on March 25, 2009.
Preferred Stock
The shares of preferred stock have such rights and preferences as the Companys Board of Directors
shall determine, from time to time. The Board of Directors may divide the Preferred Stock into any
number of series and shall fix the designation and number of shares of each such series. The Board
of Directors may determine and alter the rights, powers, preferences and privileges, and
qualifications, restrictions and limitations thereof, including, but not limited to, voting rights
(if any), granted to and imposed upon any wholly unissued series of preferred stock. The Board of
Directors (within the limits and restrictions of any resolutions adopted originally fixing the
number of shares of any series) may increase or decrease the number of shares of that series;
provided, that no such decrease shall reduce the number of shares of such series to a number less
than the number of shares of such series then outstanding plus the number of shares reserved for
issuance upon the exercise of outstanding options, rights or warrants or upon the conversion of any
outstanding securities issued by the Corporation convertible into shares of such series.
The Companys common stock is subject to the express terms of the Companys preferred stock and any
series thereof. The Board of Directors may issue preferred stock with voting, dividend,
liquidation and other rights that could adversely affect the relative rights of the holders of the
Companys common stock.
Anti-Takeover Effects of Certain Provisions of the Companys Certificate of Incorporation and
Bylaws
Certain provisions of the Companys certificate of incorporation and bylaws, which are summarized
in the following paragraphs, may have an anti-takeover effect and may delay, defer or prevent a
tender offer or takeover attempt that a stockholder might consider in its best interest, including
those attempts that might result in a premium over the market price for the shares held by
stockholders.
Classified Board
The Companys certificate of incorporation provides that the Companys Board of Directors will be
divided into three classes of directors, with the classes to be as nearly equal in number as
possible. As a result, approximately one-third of the Companys Board of Directors will be elected
each year. The Companys bylaws provide that the number of directors will be fixed from time to
time exclusively pursuant to a resolution adopted by the board.
Removal of Directors; Vacancies
Under the Delaware General Corporation Law (DGCL), and pursuant to the Companys bylaws,
directors serving on a classified board may be removed by the stockholders only for cause. In
addition, the Companys bylaws also provide that any vacancies on the Companys Board of Directors
will be filled only by the affirmative vote of a majority of the remaining directors then in
office, even if less than a quorum.
Delaware Anti-Takeover Statute
The Company is subject to Section 203 of the DGCL. Subject to specified exceptions, Section 203
prohibits a publicly held Delaware corporation from engaging in a business combination with an
interested stockholder for a period of three years after the time of the transaction in which the
person became an interested stockholder without the prior approval of the Companys Board of
Directors or the subsequent approval of the Companys Board of Directors and the Companys
stockholders. Business combinations include mergers, asset sales and other transactions
resulting in a financial benefit to the interested stockholder. Subject to various exceptions,
an interested stockholder is a person who, together with his or her affiliates and associates,
owns, or within three years did own, 15% or more of the corporations outstanding voting stock.
These restrictions may prohibit or delay the accomplishment of mergers or other takeover or change
in control attempts.
Stockholder Action
The
Companys bylaws require a stockholders notice to be delivered to, or mailed and received at,
the Companys principal executive office not less than 90 days nor more than 120 days prior to a
scheduled annual meeting, provided that if the meeting date is moved more than 30 days
before or after the anniversary of the prior years meeting, then notice shall be required to be
given within 10 days from the time that the annual meeting date is first publicly announced. The
Companys stockholders do not have the ability to act by written consent and do not have the
ability to call special meetings of stockholders. Where a stockholder vote is needed to amend the
Bylaws or the Certificate of Incorporation of the Company, a 75% vote will be required unless such
amendment is recommended by the board of directors, in which case only a majority vote is required.
Transfer Agent and Registrar
American Stock Transfer & Trust Company, LLC is the transfer agent and registrar for the Companys
common stock.
Listing
The Companys common stock is listed on the Nasdaq Global Market under the symbol AVNR.
The foregoing description of the Companys common stock does not purport to be complete and is
qualified in its entirety by reference to the Companys certificate of incorporation and bylaws,
copies of which are filed as exhibits to the Companys current report on Form 8-K filed March 25,
2009 and are hereby incorporated herein by reference.
Item 2. Exhibits.
|
|
|
Exhibit |
|
|
Number |
|
Description of Exhibit |
|
|
|
3.1
|
|
Certificate of Incorporation of the Company (1) |
|
|
|
3.2
|
|
Bylaws of the Company (1) |
|
|
|
3.3
|
|
Certificate of Designations for Series A Junior Participating Cumulative Preferred Stock (2) |
|
|
|
4.1
|
|
Form of Common Stock Certificate (1) |
|
|
|
4.2
|
|
Stockholder Rights Agreement, dated as of March 20, 2009, by and between the Company and
American Stock Transfer & Trust Company, LLC (2) |
|
|
|
4.3
|
|
Form of Rights Certificate with respect to the Stockholder Rights Agreement (filed as part
of Exhibit 4.2) (2) |
|
|
|
(1) |
|
Filed with the Companys Current Report on Form 8-K, filed with the Securities and
Exchange Commission on March 25, 2009, and incorporated by reference herein. |
|
|
|
(2) |
|
Filed with the Companys Amendment No. 3 to Registration Statement on Form 8-A, filed
with the Securities and Exchange Commission on March 25, 2009, and incorporated by
reference herein. |
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the
registrant has duly caused this registration statement to be signed its behalf by the undersigned
thereunto duly authorized.
Dated: March 25, 2009
|
|
|
|
|
|
AVANIR PHARMACEUTICALS, INC.
|
|
|
By: |
/s/ Christine G. Ocampo
|
|
|
|
Christine G. Ocampo |
|
|
|
Vice President, Finance |
|
|
Exhibit Index
|
|
|
Exhibit |
|
|
Number |
|
Description of Exhibit |
|
|
|
3.1
|
|
Certificate of Incorporation of the Company (1) |
|
|
|
3.2
|
|
Bylaws of the Company (1) |
|
|
|
3.3
|
|
Certificate of Designations for Series A Junior Participating Cumulative Preferred Stock (2) |
|
|
|
4.1
|
|
Form of Common Stock Certificate (1) |
|
|
|
4.2
|
|
Stockholder Rights Agreement, dated as of March 20, 2009, by and between the Company and
American Stock Transfer & Trust Company, LLC (2) |
|
|
|
4.3
|
|
Form of Rights Certificate with respect to the Stockholder Rights Agreement (filed as part
of Exhibit 4.2) (2) |
|
|
|
(1) |
|
Filed with the Companys Current Report on Form 8-K, filed with the Securities and
Exchange Commission on March 25, 2009, and incorporated by reference herein. |
|
(2) |
|
Filed with the Companys Amendment No. 3 to Registration Statement on Form 8-A, filed
with the Securities and Exchange Commission on March 25, 2009, and incorporated by
reference herein. |